Not only that but the EV of Race (i.e. minus cash on hand) is rapidly approaching USD100 million. Further depreciation in the share price and/or AUD will knock it into double digits. Surely there's a point where it becomes attractive for someone to try and pick up the lot. Clinical effectiveness in AML alone should justify the current price, and they could get cardio-protection, FTO, RC220 (plus the other formulation alluded to), and everything else thrown in as a gamble.
Ann: Race Strategic Update August 2023, page-156
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |